Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.25: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 1.85; Below-average business quality.
Syndax Pharmaceuticals is a commercial-stage biopharma with two FDA-approved oncology products: Revuforj (revumenib, launched Nov 2024) for R/R acute leukemia with KMT2A translocation or NPM1 mutation, and Niktimvo (axatilimab-csfr, launched Jan 2025) for cGVHD after two prior... Read more
Sell if holding. Engine safety override at $18.25: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 1.85; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-14Recent Developments — Syndax Pharmaceuticals, Inc.
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target — benzinga Jun 12, 2026 positive
- NEWS Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 Congress — benzinga Jun 11, 2026 positive
- NEWS Syndax Presents Key Revuforj Data At EHA 2026 Congress; Real-World Study Of Revumenib Shows 82% ORR And 64% CR/CRh Rate — benzinga Jun 11, 2026 positive
- NEWS Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And — benzinga Jun 11, 2026 positive
- NEWS Syndax Pharma Enters Into Privately Negotiated Subscription Agreements For Issuance Of $250M Aggregate Principal Amount — benzinga Jun 4, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRevuforj and Niktimvo10-K Item 1A: 'Our business depends heavily on our ability to successfully commercialize Revuforj and Niktimvo in the United States'
- HIGHcounterpartyIncyte10-K Item 1A: 'We are dependent upon our collaboration with Incyte to further develop and commercialize axatilimab.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.25: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 1.85; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.97. Score 5.0/10, moderate confidence.
Take-profit target: $33.93 (+85.9% upside). Prior stop was $16.97. Stop-loss: $16.97.
Concentration risk — Product: Revuforj and Niktimvo; Concentration risk — Counterparty: Incyte; Quality below floor (2.5 < 4.0).
Syndax Pharmaceuticals, Inc. trades at a P/E of N/A (forward -33.5). TrendMatrix value score: 7.5/10. Verdict: Sell.
20 analysts cover SNDX with a consensus score of 4.3/5. Average price target: $39.
What does Syndax Pharmaceuticals, Inc. do?Syndax Pharmaceuticals is a commercial-stage biopharma with two FDA-approved oncology products: Revuforj (revumenib,...
Syndax Pharmaceuticals is a commercial-stage biopharma with two FDA-approved oncology products: Revuforj (revumenib, launched Nov 2024) for R/R acute leukemia with KMT2A translocation or NPM1 mutation, and Niktimvo (axatilimab-csfr, launched Jan 2025) for cGVHD after two prior lines of therapy, the latter co-commercialized with Incyte. The company has never previously marketed a product and generates revenue primarily from Revuforj and Niktimvo sales.